Guardant Health, Inc.
Key Metrics
- Previous Close
- $143.28
- 52-Week Range
- $74.55 – $191.05
- Market Cap
- $19.64B
- P/E (TTM)
- —
- EPS (TTM)
- -3.68
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- —
- PEG Ratio
- —
- Return on Equity
- —
- Return on Assets
- -19.92%
- Gross Margin
- 65.19%
- Operating Margin
- -39.40%
- Profit Margin
- -37.93%
- Current Ratio
- 3.60
- Debt/Equity
- —
- Total Debt
- $1.69B
- Free Cash Flow
- $-60.54M
- Revenue Growth
- 36.10%
- Earnings Growth
- —
- Enterprise Value
- $20.30B
Market Snapshot
About
Guardant Health, Inc. is a precision oncology company focused on developing and commercializing blood-based liquid biopsy tests for cancer screening, diagnosis, and treatment monitoring. The company's flagship products include Guardant360, a comprehensive genomic profiling test for advanced cancer patients, and Guardant Reveal for minimal residual disease detection and recurrence monitoring. Guardant's Shield test is a blood-based screening solution for colorectal cancer in average-risk individuals. The company's liquid biopsy platform analyzes circulating tumor DNA (ctDNA) in blood samples, offering a less invasive alternative to traditional tissue biopsies. Guardant Health is at the forefront of precision medicine, partnering with pharmaceutical companies and healthcare providers to improve cancer outcomes.